Interactive Computer Treatment for Panic Disorder - Full Text View

Sponsor:	National Institute of Mental Health (NIMH)
Information provided by:	National Institute of Mental Health (NIMH)
ClinicalTrials.gov Identifier:	NCT00063375

Purpose

This study will develop an interactive computer-based version of cognitive behavioral therapy (CBT) and compare its effectiveness to book-based CBT for the treatment of panic disorder.

Condition	Intervention	Phase
Panic Disorder	Behavioral: Computer Based Cognitive Behavioral Therapy	Phase I

Study Type:	Interventional
Study Design:	Allocation: Randomized Endpoint Classification: Efficacy Study Intervention Model: Parallel Assignment Masking: Open Label Primary Purpose: Treatment
Official Title:	Interactive Computer Treatment for Panic Disorder

Resource links provided by NLM:

MedlinePlus related topics: Panic Disorder

U.S. FDA Resources

Further study details as provided by National Institute of Mental Health (NIMH):

Estimated Enrollment:	60
Study Start Date:	January 2002
Primary Completion Date:	February 2007 (Final data collection date for primary outcome measure)

Detailed Description:

Panic disorder (PD) is a highly prevalent and debilitating condition. Unfortunately, many people with PD go untreated because of the high cost and low availability of treatment. Research shows that CBT is an effective treatment for PD. When administered as a self-help, computer based treatment, CBT may provide a less expensive, more engaging treatment for PD.

Participants in this study will be randomly assigned to receive computer based treatment, book based treatment, or no treatment for 10 weeks. After these 10 weeks, symptoms of anxiety and depression will be measured with patient interviews, scales, and questionnaires.

Eligibility

Ages Eligible for Study:	18 Years to 65 Years
Genders Eligible for Study:	Both
Accepts Healthy Volunteers:	No

Criteria

Inclusion Criteria:

DSM-IV diagnosis of panic disorder, with or without agoraphobia

Exclusion Criteria:

Change in medication type or dose 12 weeks prior to study entry
Suicidal
Current substance abuse
Current or past schizophrenia, bipolar disorder, or organic mental disorder. Patients on medications must meet stability requirements such that initial administration of the medication and dose has been maintained for at least 3 months prior to treatment and will be maintained until post-treatment.

Contacts and Locations

Please refer to this study by its ClinicalTrials.gov identifier: NCT00063375

Locations

United States, Florida
Florida State University
Tallahassee, Florida, United States, 32306

Sponsors and Collaborators

National Institute of Mental Health (NIMH)

More Information

No publications provided

ClinicalTrials.gov Identifier:	NCT00063375 History of Changes
Other Study ID Numbers:	R21 MH62056, DSIR AT-AS
Study First Received:	June 25, 2003
Last Updated:	February 8, 2008
Health Authority:	United States: Federal Government

Additional relevant MeSH terms:

Panic Disorder
Anxiety Disorders
Mental Disorders

ClinicalTrials.gov processed this record on February 09, 2012